{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:51:18Z","timestamp":1788202278104,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V110B-008"],"award-info":[{"award-number":["V110B-008"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00432-022-04396-1","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T03:03:02Z","timestamp":1667271782000},"page":"5-14","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis"],"prefix":"10.1007","volume":"149","author":[{"given":"Chi-Lu","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Ling","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chen","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Chia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsu-Ching","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-I","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Hung","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hua","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teh-Ying","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"issue":"4","key":"4396_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","volume":"15","author":"MJ Ahn","year":"2020","unstructured":"Ahn MJ, Chiu CH, Cheng Y, Han JY, Goldberg SB, Greystoke A, Mok T (2020) Osimertinib for patients With leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis. J Thorac Oncol 15(4):637\u2013648. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.113","journal-title":"J Thorac Oncol"},{"issue":"5","key":"4396_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/neuonc\/noz012","volume":"21","author":"A Boire","year":"2019","unstructured":"Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, Junck L, Soffietti R (2019) Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro Oncol 21(5):571\u2013584. https:\/\/doi.org\/10.1093\/neuonc\/noz012","journal-title":"Neuro Oncol"},{"issue":"4","key":"4396_CR3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/neuonc\/now183","volume":"19","author":"M Chamberlain","year":"2017","unstructured":"Chamberlain M, Junck L, Brandsma D, Soffietti R, Rud\u00e0 R, Raizer J, Jaeckle KA (2017) Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol 19(4):484\u2013492. https:\/\/doi.org\/10.1093\/neuonc\/now183","journal-title":"Neuro Oncol"},{"issue":"1","key":"4396_CR4","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/s1470-2045(17)30689-7","volume":"19","author":"H Cheng","year":"2018","unstructured":"Cheng H, Perez-Soler R (2018) Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol 19(1):e43\u2013e55. https:\/\/doi.org\/10.1016\/s1470-2045(17)30689-7","journal-title":"Lancet Oncol"},{"issue":"4","key":"4396_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11523-020-00737-7","volume":"15","author":"CL Chiang","year":"2020","unstructured":"Chiang CL, Huang HC, Shen CI, Luo YH, Chen YM, Chiu CH (2020) Post-progression survival in secondary EGFR T790M-mutated non-small-cell lung cancer patients with and without osimertinib after failure of a previous EGFR TKI. Target Oncol 15(4):503\u2013512. https:\/\/doi.org\/10.1007\/s11523-020-00737-7","journal-title":"Target Oncol"},{"issue":"12","key":"4396_CR6","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.52586\/5060","volume":"26","author":"CL Chiang","year":"2021","unstructured":"Chiang CL, Huang HC, Luo YH, Chiu CH (2021a) Cerebrospinal fluid as a medium of liquid biopsy in the management of patients with non-small-cell lung cancer having central nervous system metastasis. Front Biosci (landmark Ed) 26(12):1679\u20131688. https:\/\/doi.org\/10.52586\/5060","journal-title":"Front Biosci (landmark Ed)"},{"issue":"2","key":"4396_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11523-021-00791-9","volume":"16","author":"CL Chiang","year":"2021","unstructured":"Chiang CL, Lee CC, Huang HC, Wu CH, Yeh YC, Shen CI, Chiu CH (2021b) Utility of cerebrospinal fluid cell-free DNA in patients with EGFR-mutant non-small-cell lung cancer with leptomeningeal metastasis. Target Oncol 16(2):207\u2013214. https:\/\/doi.org\/10.1007\/s11523-021-00791-9","journal-title":"Target Oncol"},{"issue":"8","key":"4396_CR8","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","volume":"16","author":"C Fan","year":"2021","unstructured":"Fan C, Zhao Q, Li L, Shen W, Du Y, Teng C, Xin T (2021) Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from EGFR-mutant NSCLC-a prospective, open-label, single-arm phase 1\/2 clinical trial (unique identifier: ChiCTR1800016615). J Thorac Oncol 16(8):1359\u20131368. https:\/\/doi.org\/10.1016\/j.jtho.2021.04.018","journal-title":"J Thorac Oncol"},{"issue":"4","key":"4396_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.cllc.2017.01.013","volume":"18","author":"J How","year":"2017","unstructured":"How J, Mann J, Laczniak AN, Baggstrom MQ (2017) Pulsatile erlotinib in EGFR-positive non-small-cell lung cancer patients with leptomeningeal and brain metastases: review of the literature. Clin Lung Cancer 18(4):354\u2013363. https:\/\/doi.org\/10.1016\/j.cllc.2017.01.013","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"4396_CR10","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jtho.2017.05.002","volume":"12","author":"S Jenkins","year":"2017","unstructured":"Jenkins S, Yang JC, J\u00e4nne PA, Thress KS, Yu K, Hodge R, Shepherd FA (2017) EGFR mutation analysis for prospective patient selection in two phase II registration studies of osimertinib. J Thorac Oncol 12(8):1247\u20131256. https:\/\/doi.org\/10.1016\/j.jtho.2017.05.002","journal-title":"J Thorac Oncol"},{"key":"4396_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.lungcan.2018.10.027","volume":"126","author":"T John","year":"2018","unstructured":"John T, Akamatsu H, Delmonte A, Su WC, Lee JS, Chang GC, Wu YL (2018) EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. Lung Cancer 126:133\u2013138. https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.027","journal-title":"Lung Cancer"},{"issue":"3","key":"4396_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.lungcan.2015.05.023","volume":"89","author":"JL Kuiper","year":"2015","unstructured":"Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, Thunnissen E, Smit EF (2015) Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis. Lung Cancer 89(3):255\u2013261. https:\/\/doi.org\/10.1016\/j.lungcan.2015.05.023","journal-title":"Lung Cancer"},{"issue":"suppl_4","key":"4396_CR13","doi-asserted-by":"publisher","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","volume":"28","author":"E Le Rhun","year":"2017","unstructured":"Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Preusser M (2017) EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol 28(suppl_4):iv84\u2013iv99. https:\/\/doi.org\/10.1093\/annonc\/mdx221","journal-title":"Ann Oncol"},{"issue":"11","key":"4396_CR14","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.jtho.2020.06.018","volume":"15","author":"J Lee","year":"2020","unstructured":"Lee J, Choi Y, Han J, Park S, Jung HA, Su JM, Ahn MJ (2020) Osimertinib improves overall survival in patients with EGFR-mutated NSCLC with leptomeningeal metastases regardless of T790M mutational status. J Thorac Oncol 15(11):1758\u20131766. https:\/\/doi.org\/10.1016\/j.jtho.2020.06.018","journal-title":"J Thorac Oncol"},{"issue":"11","key":"4396_CR15","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","volume":"11","author":"YS Li","year":"2016","unstructured":"Li YS, Jiang BY, Yang JJ, Tu HY, Zhou Q, Guo WB, Wu YL (2016) Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol 11(11):1962\u20131969. https:\/\/doi.org\/10.1016\/j.jtho.2016.06.029","journal-title":"J Thorac Oncol"},{"issue":"4","key":"4396_CR16","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/annonc\/mdy009","volume":"29","author":"YS Li","year":"2018","unstructured":"Li YS, Jiang BY, Yang JJ, Zhang XC, Zhang Z, Ye JY, Wu YL (2018) Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. Ann Oncol 29(4):945\u2013952. https:\/\/doi.org\/10.1093\/annonc\/mdy009","journal-title":"Ann Oncol"},{"issue":"1","key":"4396_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12931-021-01741-9","volume":"22","author":"C Li","year":"2021","unstructured":"Li C, Nie W, Guo J, Xiong A, Zhong H, Chu T, Zhang X (2021) Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation. Respir Res 22(1):145. https:\/\/doi.org\/10.1186\/s12931-021-01741-9","journal-title":"Respir Res"},{"issue":"7","key":"4396_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Papadimitrakopoulou VA (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376(7):629\u2013640. https:\/\/doi.org\/10.1056\/NEJMoa1612674","journal-title":"N Engl J Med"},{"issue":"1","key":"4396_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/bjc.2017.394","volume":"118","author":"S Nanjo","year":"2018","unstructured":"Nanjo S, Hata A, Okuda C, Kaji R, Okada H, Tamura D, Katakami N (2018) Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. Br J Cancer 118(1):32\u201337. https:\/\/doi.org\/10.1038\/bjc.2017.394","journal-title":"Br J Cancer"},{"issue":"10","key":"4396_CR20","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","volume":"31","author":"S Park","year":"2020","unstructured":"Park S, Lee MH, Seong M, Kim ST, Kang JH, Cho BC, Ahn MJ (2020) A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Ann Oncol 31(10):1397\u20131404. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.017","journal-title":"Ann Oncol"},{"key":"4396_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ctrv.2016.12.006","volume":"53","author":"J Remon","year":"2017","unstructured":"Remon J, Le Rhun E, Besse B (2017) Leptomeningeal carcinomatosis in non-small cell lung cancer patients: a continuing challenge in the personalized treatment era. Cancer Treat Rev 53:128\u2013137. https:\/\/doi.org\/10.1016\/j.ctrv.2016.12.006","journal-title":"Cancer Treat Rev"},{"key":"4396_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.78.3118","author":"T Reungwetwattana","year":"2018","unstructured":"Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Vansteenkiste J (2018) CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2018.78.3118","journal-title":"J Clin Oncol"},{"issue":"2","key":"4396_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Ramalingam SS (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378(2):113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"4396_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.lungcan.2020.07.034","volume":"148","author":"M Suryavanshi","year":"2020","unstructured":"Suryavanshi M, Jaipuria J, Panigrahi MK, Goyal N, Singal R, Mehta A, Talwar V (2020) CSF cell-free DNA EGFR testing using DdPCR holds promise over conventional modalities for diagnosing leptomeningeal involvement in patients with non-small cell lung cancer. Lung Cancer 148:33\u201339. https:\/\/doi.org\/10.1016\/j.lungcan.2020.07.034","journal-title":"Lung Cancer"},{"issue":"1","key":"4396_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jtho.2021.08.009","volume":"17","author":"NJ Thomas","year":"2022","unstructured":"Thomas NJ, Myall NJ, Sun F, Patil T, Mushtaq R, Yu C, McCoach CE (2022) Brain metastases in EGFR- and ALK-positive NSCLC: outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation. J Thorac Oncol 17(1):116\u2013129. https:\/\/doi.org\/10.1016\/j.jtho.2021.08.009","journal-title":"J Thorac Oncol"},{"issue":"6","key":"4396_CR26","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1634\/theoncologist.2018-0264","volume":"24","author":"L Xie","year":"2019","unstructured":"Xie L, Nagpal S, Wakelee HA, Li G, Soltys SG, Neal JW (2019) Osimertinib for EGFR-mutant lung cancer with brain metastases: results from a single-center retrospective study. Oncologist 24(6):836\u2013843. https:\/\/doi.org\/10.1634\/theoncologist.2018-0264","journal-title":"Oncologist"},{"issue":"11","key":"4396_CR27","doi-asserted-by":"publisher","first-page":"937","DOI":"10.21037\/atm-21-1249","volume":"9","author":"H Xu","year":"2021","unstructured":"Xu H, Chen H, Kong J, Zhang Y, Liu S, Yang G, Wang Y (2021) Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status. Ann Transl Med 9(11):937. https:\/\/doi.org\/10.21037\/atm-21-1249","journal-title":"Ann Transl Med"},{"issue":"6","key":"4396_CR28","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1002\/cam4.2156","volume":"8","author":"W Yan","year":"2019","unstructured":"Yan W, Jing W, An N, Tian Y, Guo D, Kong L, Yu J (2019a) The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer institute. Cancer Med 8(6):2769\u20132776. https:\/\/doi.org\/10.1002\/cam4.2156","journal-title":"Cancer Med"},{"issue":"1","key":"4396_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13014-019-1376-z","volume":"14","author":"W Yan","year":"2019","unstructured":"Yan W, Liu Y, Li J, Han A, Kong L, Yu J, Zhu H (2019b) Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis. Radiat Oncol 14(1):168. https:\/\/doi.org\/10.1186\/s13014-019-1376-z","journal-title":"Radiat Oncol"},{"issue":"3","key":"4396_CR30","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ijrobp.2021.05.125","volume":"111","author":"F Yu","year":"2021","unstructured":"Yu F, Ni J, Zeng W, Zhou Y, Guo T, Zeng Y, Zhu Z (2021) Clinical value of upfront cranial radiation therapy in osimertinib-treated epidermal growth factor receptor-mutant non-small cell lung cancer with brain metastases. Int J Radiat Oncol Biol Phys 111(3):804\u2013815. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.05.125","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"4396_CR31","doi-asserted-by":"publisher","first-page":"8366","DOI":"10.18632\/oncotarget.3187","volume":"6","author":"YD Zeng","year":"2015","unstructured":"Zeng YD, Liao H, Qin T, Zhang L, Wei WD, Liang JZ, Chen LK (2015) Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. Oncotarget 6(10):8366\u20138376. https:\/\/doi.org\/10.18632\/oncotarget.3187","journal-title":"Oncotarget"},{"issue":"2","key":"4396_CR32","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jtho.2020.10.008","volume":"16","author":"MM Zheng","year":"2021","unstructured":"Zheng MM, Li YS, Tu HY, Jiang BY, Yang JJ, Zhou Q, Wu YL (2021) Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated NSCLC. J Thorac Oncol 16(2):250\u2013258. https:\/\/doi.org\/10.1016\/j.jtho.2020.10.008","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04396-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04396-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04396-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T02:31:42Z","timestamp":1675132302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04396-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["4396"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04396-1","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"assertion":[{"value":"2 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CLC had received honoraria from AstraZeneca, Boehringer Ingelheim, Pfizer, and Roche. YHL had received honoraria from AstraZeneca, Boehringer Ingelheim, and Pfizer. YMC had received honoraria from Boehringer Ingelheim, Eli Lilly, Roche\/Genentech\/Chugai, MSD, Pfizer, Novartis, BMS, Ono Pharmaceutical, AstraZeneca, and Takeda Oncology; and served as advisor for Boehringer Ingelheim, Eli Lilly, Roche\/Chugai, MSD, AstraZeneca, and Takeda Oncology. CHC had received honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Janssen, Merck KGaA, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, Roche, and Takeda. Others declare no conflict of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of Taipei Veterans General Hospital, Taiwan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}